ResearcherUniversity of ViennaNo recent work listed
Philipp Buchner
Matched on OpenAlex author ID A5001330094.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 2 (first author 0, last author 1)
- Pancreatic cancer trials
- 0
- Pancreatic cancer grants
- 0
- Collaborators
- 3
2018: 1 paper · 2019: 1 paper
Papers 2
- Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Last author DOI 10.1007/s10637-018-0639-0↗
- Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. Co-author DOI 10.1007/s00280-018-3545-4↗
Closest collaborators
The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Azra Sahmanovic Hrgovcic · 2 shared papers, 2018–2019
- Paper Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. DOI 10.1007/s10637-018-0639-0↗
- Paper Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiological… DOI 10.1007/s00280-018-3545-4↗
- Christian Dittrich · 2 shared papers, 2018–2019
- Paper Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. DOI 10.1007/s10637-018-0639-0↗
- Paper Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiological… DOI 10.1007/s00280-018-3545-4↗
- Andrea Grüber · 1 shared paper, 2018
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.